Commission paves the way for (H1N1) vaccine

Email item Email item Print item Print item

Commission paves the way for (H1N1) vaccineFollowing the positive scientific opinion issued by the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMEA) on the 24th of September, the European Commission as now granted variations to two existing authorisations for vaccines for influenza pandemic (H1N1) 2009.

The products concerned are Focetria® (Novartis), and Pandemrix® (GlaxoSmithKline). The vaccines will be authorised for use in all Member States of the EU and the EEA (Iceland, Liechtenstein and Norway). That should ensure that sufficient vaccines will be available before the start of the flu season and will reduce the risks for illnesses and deaths for European Citizens.

Commissioner Verheugen states, “I am very satisfied that the Commission was able to decide in the shortest possible time. I wish to thank everybody, all the people who worked day and night to make this happen.”

The authorisation takes effect upon their notification to the marketing authorisation holder, which the Commission ensures via express courier and is to be expected by Thursday, the 1st of October at the latest.

The authorisations will be available in all official languages and are sent to the Member States.

  • Permalink: Commission paves the way for (H1N1) vaccine
  • You may also like...

    Leave a Reply

    Your email address will not be published. Required fields are marked *